Tome Yasunori, Kimura Hiroaki, Kiyuna Tasuku, Sugimoto Naotoshi, Tsuchiya Hiroyuki, Kanaya Fuminori, Bouvet Michael, Hoffman Robert M
AntiCancer, Inc., San Diego, CA 92111, USA.
Department of Surgery, University of California, San Diego, CA 92103, USA.
Oncotarget. 2016 Jul 19;7(29):46315-46320. doi: 10.18632/oncotarget.10111.
The in vitro efficacy of the disintegrin echistatin was tested on a high-metastatic variant of 143B human osteosarcoma, 143B-LM4, which over-expresses αvβ3 integrin. Echistatin is an RGD cyclic peptide and an antagonist of αvβ3 integrin. In the present study, echistatin inhibited cell proliferation, migration, invasion, and adhesion of 143B-LM4 cells. 143B-LM4 cell proliferation decreased after treatment with echistatin in a time-dependent and dose-dependent manner (P <0.01). In vitro migration and invasion of 143B-LM4 cells were also inhibited by echistatin in a dose-dependent manner (P <0.01, respectively). Cell adhesion to vitronectin of 143B-LM4 cells was also inhibited by echistatin in a dose-dependent manner (P <0.01). These results suggest that αvβ3 integrin may be an effective target for osteosarcoma.
在过表达αvβ3整合素的人骨肉瘤高转移变体143B-LM4上测试了整合素抑制剂echistatin的体外疗效。Echistatin是一种RGD环肽，也是αvβ3整合素的拮抗剂。在本研究中，echistatin抑制了143B-LM4细胞的增殖、迁移、侵袭和黏附。用echistatin处理后，143B-LM4细胞的增殖呈时间和剂量依赖性下降（P<0.01）。Echistatin还以剂量依赖性方式抑制143B-LM4细胞的体外迁移和侵袭（分别为P<0.01）。Echistatin也以剂量依赖性方式抑制143B-LM4细胞与玻连蛋白的黏附（P<0.01）。这些结果表明，αvβ3整合素可能是骨肉瘤的有效靶点。
